Novo Nordisk nach Split WKN: A3EU6F ISIN: DK0062498333 Kürzel: NOV Forum: Aktien User: Coronaprofiteur

Wie gestern angekündigt heute das golden cross bei den ADRs. Nützt natürlich nix wenn novo morgen nicht liefert. Aber ich denke sie werden liefern

Hör auf, McDonald’s hab ich (b)auch!!!

Mit welcher Begründung Pinocchio. Siehst du die Börsenkurse von den Aktien in deiner 🔮😱🙈🤔 Wie hoch sind deine Verluste bei Schaeffler, Depfa,HD,Stellantis, Nucera,Evotec usw.❓️📉⬇️ Demo Depot Verluste sind doch garkeine oder ❓️💶🚽

McDonalds mit einem revenue miss, bullish für glp-1 😀

Liest sich alles richtig gut

Der ganze FT Artikel ohne paywll hier: *** https://archive.is/Fv42D

Mike Doustdar called Oral Wegovy sales "phenomenal" and said LLY's launch of Foundayo has not reduced demand. Instead, Novo has seen demand for Oral Wegovy continue to accelerate.

🇩🇰 SB1 Markets reiterates Buy on $NVO with a DKK 360 price target. Ahead of tomorrow's earnings, they highlight that oral Wegovy now accounts for more than one-third of all Wegovy prescriptions in the US and view the prescription data as supporting a successful US launch.

The last part about NVO/ wegovy pill being ahead $LLY Foundayo everywhere wegovy pill has been launched. Well currently it’s only in US and UAE both pills are launched. In UAE Foundayo was launched about 1 month before wegovy pill. Rumours say wegovy pill is outselling Foundayo more than 2:1. But I have not seen any actual data yet, so for now it’s still just rumours. But the way Doustdar frames it, then wegovy pill have very likely passed Foundayo even though it was the last one to be launched

Macht doch nichts! Du scheinst so pleite zu sein das dein Magen eh leer ist!

Ely Lilly Übernahme 😁👍

Doustdar also signalled he would consider far bigger deals than Pfizer’s $10bn acquisition of obesity drug developer Metsera after a takeover battle with Novo, saying that was not a “large” transaction in his eyes.

Arrogance kills’: Novo chief injects risk-taking into Ozempic maker https://archive.is/2026.08.04-045736/https://www.ft.com/content/d44d9139-c6ac-41de-851d-ab30b6085ce2?syn-25a6b1a6=1

Vielleicht können Sie schon jetzt ein größeres Rad drehen, weil langsam aus den Investitionen auch Geld zurück kommt 🤔🔮

Im Frühjahr war noch von 40mrd die Rede.

As $NVO attempts to expand its pipeline and diversify its portfolio, Doustdar said he was open to “big” mergers and acquisitions. “Probably today we are in more data rooms than ever before looking into anything and everything that is out there.” But he stressed that the company prioritised assets that fill gaps in its portfolio over size.” That’s NVO CEO in a fresh interview with Financial Times. When you reach the level of being in their data room, then you are doing hardcore DD, preparing to make an offer for those that live up to their desired criteria. I think they will announce M&A before their upcoming CMD in September. With ziltivekimab failure last Friday, they will also be even more active to fill the pipeline with assets outside obesity/T2D “I do think that we need to diversify, no doubt about it, but I think we need to have disciplined diversifications around science areas and customer populations that we are synonymous with,” he said. NVO can do $50B if they see the right fits. But they still need to be disciplined and not overpay. I would like to see them get even bigger foothold in Chinese R&D. To get more acces to the lightning speed of development in China. $LLY $VKTX ft.com/content/d44d91…